Floatz logo

Polio Vaccine

Bladder Cancer

National Cancer Institute (NCI)vaccinePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
73/ 100

Competitive context

121 Active assets in the Bladder Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
VINBLASTINE
University of Southern California
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Polio Vaccine is also rated in:

Immunity to Polio Vaccines in Malnourished InfantsDormant
B
Indicative ·
56 / 100
View asset →
colon carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
breast cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →